Executive Order on Promoting Competition in the American Economy: A Focus on Patent and Drug Law to Reduce Health Care Spending

Each year, Americans spend more than $1,500 per person on prescription drugs. Critics calling for measures to lower prescription drug costs often cast blame on alleged abuses of patent and competition laws. To address these perceived abuses, President Biden issued an "Executive Order on Promoting Competition in the American Economy" focused on increasing competition in several industries, including the pharmaceutical and biotechnology industries. In response, executive agencies and members of Congress have recently issued reports and letters addressing the concerns and directives presented in President Biden's executive order.

This Jones Day White Paper outlines: (i) President Biden's executive order and documents issued in response; (ii) proposed changes to the U.S. patent and drug regulatory regimes; and (iii) potential effects of those proposals on the pharmaceutical and biotechnology industries.

Read the White Paper.

Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.